- Durable complete regressions observed in 50% of mice in a RAS-mutant colorectal cancer model treated with Atebimetinib plus anti-PD-1, with no regrowth even after dosing stopped - - Median survival extended by 1.8-fold with atebimetinib plus anti-PD-1 and chemotherapy versus anti-PD-1 plus chemotherapy alone in a RAS-mutant lung cancer model - - Pulsatile MEK inhibition reversed MAPK-driven immune suppression by lowering suppressive myeloid cells and regulatory T-cells, and expanding NK cells, while avoiding T-cell signaling attenuation associated with continuous MAPK inhibition - - Phase 2 clinical trial of atebimetinib in combination with anti-PD-1 and platinum-doublet chemotherapy in first-line RAS-mutant NSCLC is expected to dose the first patient by year-end - NEW YORK, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced compelling preclinical data demonstrating that atebimetinib, the Company's novel Deep Cyclic Inhibitor of MEK, enhanced the activity of PD-1 checkpoint blockade in RAS-mutant colorectal and lung cancer models, including a 50% durable complete regression rate in a colorectal model and a 1.8-fold median survival improvement with a triple combination in a lung model. The data are being presented at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting, taking place November 4-8, 2026, in Phoenix, Arizona.
